When the economy is barreling toward a recession, investors' first line of defense might be to abandon ship altogether. After ...

Pfizer (NYSE:PFE) recently announced positive topline results from its Phase 3 BASIS study for HYMPAVZI™ and declared a third ...

Pfizer Inc. (NYSE:PFE) is one of the Best Dividend Leaders to Buy Now. The company’s strategy focuses on steadily increasing ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment ...

Pfizer's cost-cutting boosts earnings despite revenue miss. Discover its growth strategy, strong drug portfolio & potential ...

Pfizer (NYSE:PFE) stock is a biopharmaceutical firm that had a magnificent breakout in 2021 as the worst of the pandemic sent ...

The Schwab U.S. Dividend Equity ETF yields around 4% today, which means that it would take an investment of approximately $50 ...

Pfizer Declares Third-Quarter 2025 Dividend. Board of Directors approves quarterly cash dividend of $0.43 per share. Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a ...

Income investors have liked Pfizer (NYSE: PFE) for years. However, the big drugmaker's exceptionally juicy dividend these days has made its stock even more attractive. But when a dividend yield ...

Three supercharged dividend stocks have the tools and intangibles to fatten investors' pocketbooks in June, and well beyond.

Pfizer's 5.7% dividend yield, while attractive, raises significant sustainability concerns. The company's payout ratio has skyrocketed to 436%, ...

That said, Pfizer Inc. (NYSE:PFE) has a five-year average payout ratio above 101%, which may seem alarming at first. A company can’t consistently pay more in dividends than it earns.